NO20063942L - Saltformer av 4(-4-metylpiperazin-1-ylmetyl)-n-[4-metyl-3-(4-piperidin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid - Google Patents

Saltformer av 4(-4-metylpiperazin-1-ylmetyl)-n-[4-metyl-3-(4-piperidin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid

Info

Publication number
NO20063942L
NO20063942L NO20063942A NO20063942A NO20063942L NO 20063942 L NO20063942 L NO 20063942L NO 20063942 A NO20063942 A NO 20063942A NO 20063942 A NO20063942 A NO 20063942A NO 20063942 L NO20063942 L NO 20063942L
Authority
NO
Norway
Prior art keywords
salt
methyl
benzamide
phenyl
tartrate
Prior art date
Application number
NO20063942A
Other languages
English (en)
Inventor
Paul William Manley
Hans Michael Buerger
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063942(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20063942L publication Critical patent/NO20063942L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører syreaddisjonssalter av 4-[(4-metyl-1-piperazinyl)metyl]-N-[4-metyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]feny1]benzamid, som er valgt fra gruppen bestående av et tartratsalt, slik som et (D)(-) tartratsalt eller et (L)(+) tartratsalt, et hydrokloridsalt, et citratsalt, et malatsalt, et fumaratsalt, et succinatsalt, et benzoatsalt, et benzensulfonatsalt, et pamoatsalt, et formatsalt, et malonatsalt, et 1,5-naftalendisulfonatsalt, et salicylatsalt, et sykloheksansulfamatsalt, et laktatsalt, et mandelatsalt, et glutaratsalt, et adipatsalt, et squaratsalt, et vanillatsalt, et oksaloacetatsalt, et ascorbatsalt og et sulfatsalt.
NO20063942A 2004-02-04 2006-09-04 Saltformer av 4(-4-metylpiperazin-1-ylmetyl)-n-[4-metyl-3-(4-piperidin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid NO20063942L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04
PCT/EP2005/001077 WO2005075454A2 (en) 2004-02-04 2005-02-03 SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE

Publications (1)

Publication Number Publication Date
NO20063942L true NO20063942L (no) 2006-11-02

Family

ID=34837520

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063942A NO20063942L (no) 2004-02-04 2006-09-04 Saltformer av 4(-4-metylpiperazin-1-ylmetyl)-n-[4-metyl-3-(4-piperidin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid

Country Status (22)

Country Link
US (3) US20080249104A1 (no)
EP (1) EP1713792B1 (no)
JP (1) JP4937760B2 (no)
KR (2) KR20060135735A (no)
CN (1) CN100558723C (no)
AR (1) AR047530A1 (no)
AU (1) AU2005211514B2 (no)
BR (1) BRPI0507464A (no)
CA (1) CA2553887C (no)
EC (1) ECSP066752A (no)
IL (1) IL177005A (no)
MA (1) MA28428B1 (no)
MY (1) MY144177A (no)
NO (1) NO20063942L (no)
NZ (1) NZ548714A (no)
PE (1) PE20051096A1 (no)
PH (1) PH12013500157A1 (no)
RU (1) RU2375355C2 (no)
TN (1) TNSN06243A1 (no)
TW (1) TWI347186B (no)
WO (1) WO2005075454A2 (no)
ZA (1) ZA200605972B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
AU2006316823A1 (en) 2005-11-25 2007-05-31 Novartis Ag F,G,H,I and K crystal forms of imatinib mesylate
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
BRPI0817946A2 (pt) 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
JP2013505979A (ja) 2009-09-28 2013-02-21 メディツィニシェ ウニベルジテート ウィーン Ｐｄｇｆｒベータ阻害剤の新たな使用
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
KR20130055576A (ko) 2010-03-15 2013-05-28 낫코 파마 리미티드 고순도의 결정질 이마티닙 염기를 제조하는 방법
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
WO2013150055A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (no) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3691861B2 (ja) * 1994-09-14 2005-09-07 株式会社東芝 光ディスク用光パルス幅制御装置
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2003233946A1 (en) * 2002-03-15 2003-09-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
AU2006316823A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,G,H,I and K crystal forms of imatinib mesylate

Also Published As

Publication number Publication date
EP1713792A2 (en) 2006-10-25
US20120142697A1 (en) 2012-06-07
KR20120127525A (ko) 2012-11-21
KR20060135735A (ko) 2006-12-29
WO2005075454A2 (en) 2005-08-18
MA28428B1 (fr) 2007-02-01
IL177005A (en) 2014-05-28
EP1713792B1 (en) 2014-04-30
JP2007520518A (ja) 2007-07-26
WO2005075454A3 (en) 2006-07-27
US20080249104A1 (en) 2008-10-09
TNSN06243A1 (en) 2007-12-03
CN1914191A (zh) 2007-02-14
CN100558723C (zh) 2009-11-11
AU2005211514A1 (en) 2005-08-18
AR047530A1 (es) 2006-01-25
RU2006131548A (ru) 2008-03-10
TWI347186B (en) 2011-08-21
AU2005211514B2 (en) 2009-09-10
US8513256B2 (en) 2013-08-20
IL177005A0 (en) 2006-12-10
PE20051096A1 (es) 2006-01-23
NZ548714A (en) 2009-08-28
CA2553887C (en) 2013-04-16
MY144177A (en) 2011-08-15
US20140051853A1 (en) 2014-02-20
ECSP066752A (es) 2006-11-16
CA2553887A1 (en) 2005-08-18
RU2375355C2 (ru) 2009-12-10
JP4937760B2 (ja) 2012-05-23
BRPI0507464A (pt) 2007-07-10
ZA200605972B (en) 2007-11-28
PH12013500157A1 (en) 2014-09-08
TW200529854A (en) 2005-09-16

Similar Documents

Publication Publication Date Title
NO20063942L (no) Saltformer av 4(-4-metylpiperazin-1-ylmetyl)-n-[4-metyl-3-(4-piperidin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
NO20071138L (no) Piperazinderivater som er nyttige for behandling av gastrointestinallidelser
EA201100638A1 (ru) Тригидрохлориды производного дигидроптеридинона и способы их получения
NO20055219L (no) Nye forbindelser
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
NO20083068L (no) Optisk aktive karbamater, fremgangsmate for deres fremstilling og anvendelse derav som farmasoytiske mellomprodukter
WO2009065910A3 (en) Acid addition salts of imatinib and formulations comprising the same
NO20060379L (no) Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre
PE20060964A1 (es) Forma cristalina b de clorhidrato de (3-cian-1h-indol-7-il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona y procedimiento de preparacion
NO20073758L (no) 2-okso-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidiner anvendt som CGRP-antagonister
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
TH74677A (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
NO20064114L (no) Fremgangsmate for fremstilling av N-arylpiperazinderivater
NZ543709A (en) Use of tyrosine kinase inhibitor to treat diabetes
MX2025003814A (es) Sal farmacéuticamente aceptable y forma cristalina de un derivado de tetrahidronaftaleno y método de preparación
ATE411299T1 (de) Chlorsubstituierte guanidine
RU2010135782A (ru) КРИСТАЛИЧЕСКАЯ η- МОДИФИКАЦИЯ 4-[(4-МЕТИЛ-1-ПИПЕРА-ЗИНИЛ)МЕТИЛ]-N-[4-МЕТИЛ-3-[[4-(3-ПИРИДИНИЛ)-2-ПИРИМИ-ДИНИЛ]-АМИНО]-ФЕНИЛ] БЕНЗАМИДА МЕТАНСУЛЬФОНАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
ATE480534T1 (de) Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz
UY28498A1 (es) Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application